Skip to main content

$0.078 -0.005 (-6.02%)

High

$0.08

Low

$0.08

Trades

3

Turnover

$11,867

Volume

152,018
30 June 2023 at 3:20pm
Register to track BGT and receive email alerts.
Subject
BGT Ann: Allowance of USA Patent

BGT Ann: Initial Director Interest Notice - A Ding

BGT Ann: Initial Director Interest Notice - C Ramsey

BGT Ann: BGT - Board Changes

BGT Ann: Withdrawal of Section 203D and 249D Notices

BGT Ann: GRDC Confirms Support for Flavocide in Grain Storage

BGT Ann: Bio-Gene Update Company Presentation

BGT Ann: Appendix 4C - 31 March 2023

BGT Ann: Synergy Studies Offer Significant Commercial Opportunities

BGT Ann: Receipt of Section 203D and 249D Notices

BGT Ann: Final Director's Interest Notice - J Joughin

BGT Ann: Final Director's Interest Notice - P Beetham

BGT Ann: Board and Management Changes

BGT Ann: Bio-Gene Business Update and March Quarterly Briefing

BGT Ann: Bio-Gene Extends Commercial Development Agreement

BGT Ann: Impending Retirement of Director - James Joughin

BGT Ann: Appointment of New CFO & Company Secretary

BGT Ann: Allowance of United States Patent

BGT Ann: Bio-Gene Company Update Presentation

BGT Ann: Appendix 4D - Half Year Accounts - 31 December 2022

BGT Ann: Appendix 4C - 31 December 2022

BGT Ann: Bio-Gene Receives R&D Tax Incentive

BGT Ann: Bio-Gene and STK Agree Binding Terms on Global Collaboration

BGT Ann: Trading Halt

BGT Ann: Bio-Gene Manufacturing Update Webinar

BGT Ann: Bio-Gene Submits Application for Plant Breeders Rights

BGT Ann: Bio-Gene to Present at Biocides Europe 2022

BGT Ann: Amended Constitution

BGT Ann: Results of Meeting

BGT Ann: Bio-Gene 2022 AGM - CEO's Presentation

BGT Ann: Bio-Gene 2022 AGM Presentation

BGT Ann: Bio-Gene 2022 AGM - Chairman's Address

BGT Ann: Appendix 4C - 30 September 2022

BGT Ann: Significant Developments in Molecule Manufacturing - Update

BGT Ann: 2022 Notice of Annual General Meeting/Proxy Form

BGT Ann: Notice Required Under ASX Listing Rule 3.13.1

BGT Ann: Appendix 4G and 2022 Corporate Governance Statement

BGT Ann: Appendix 4E and 2022 Annual Report

BGT Ann: Change of Director's Interest Notice - P May

BGT Ann: Change of Director's Interest Notice - R Jagger

BGT Ann: Notification of buy-back - BGT

BGT Ann: Appendix 4C - 30 June 2022

BGT Ann: Notification of buy-back - BGT

BGT Ann: Change of Director's Interest Notice - R Jagger

BGT Ann: Change of Director's Interest Notice - R Klupacs

BGT Ann: Update on Development Program with BASF

BGT Ann: Bio-Gene to Present at Bioshares 16th Biotech Summit

BGT Ann: Investor Presentation and Overview of Appendix 4C

BGT Ann: Appendix 4C - 31 March 2022

BGT Ann: Bio-Gene Executes Commercial Development Agreement

Register to track BGT and receive email alerts.

Similar Companies

DNK
KLL
NUF
PWN
RWD
SO4
TGH